CREBBP and acute myeloid leukemia: Another p300/CBP HAT inhibitor compound, C646, could inhibit the growth of both human melanoma and non-small-cell-lung (NSCL) cancer cell lines [22], and also could inhibit the growth of primary blasts isolated from patients with t(8;21)-positive acute myelocytic leukemia (AML) as well as Kasumi-1 cells [23].